Show simple item record

Anticonvulsionantes: Profilaxis de migraña

dc.contributor.authorPalacios, Eduardospa
dc.contributor.authorPradilla, Oscarspa
dc.date.accessioned2008-09-01 00:00:00
dc.date.accessioned2022-02-21T20:37:09Z
dc.publisherSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Saludspa
dc.date.issued2008-09-01
dc.rightsFundación Universitaria de Ciencias de la Salud FUCS - 0spa
dc.sourcehttps://revistas.fucsalud.edu.co/index.php/repertorio/article/view/505spa
dc.subjectmigrañaspa
dc.subjectprofilaxisspa
dc.subjectanticonvulsivantesspa
dc.subjectácido valproicospa
dc.subjectgabapentínspa
dc.subjecttopiramatospa
dc.subjectmigraineeng
dc.subjectprophylaxiseng
dc.subjectanticonvulsantseng
dc.subjectvalproic acideng
dc.subjectgabapentineng
dc.subjecttopiramateeng
dc.titleAnticonvulsionantes: Profilaxis de migrañaspa
dc.format.mimetypeapplication/pdfspa
dc.typeArtículo de revistaspa
dc.typeJournal articleeng
dc.date.available2008-09-01 00:00:00
dc.date.available2022-02-21T20:37:09Z
dc.identifier.doi10.31260/RepertMedCir.v17.n3.2008.505
dc.identifier.issn0121-7372
dc.identifier.urihttps://repositorio.fucsalud.edu.co/handle/001/2402
dc.language.isospaspa
dc.relation.referencesCutrer FM. Antiepileptic drugs: how they work in headache. Headache. 2001 Nov-Dec;41 Suppl 1:S3-10.spa
dc.relation.referencesPost RM, Silberstein SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology. 1994 Oct;44(10 Suppl 7):S37-47.spa
dc.relation.referencesSorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand. 1988 Oct;78(4):346-8.spa
dc.relation.referencesCalabresi P, Galletti F, Rossi C, Sarchielli P, Cupini LM. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci. 2007 Apr;28(4):188-95.spa
dc.relation.referencesRamadan NM. Current trends in migraine prophylaxis. Headache. 2007 Apr;47 Suppl 1:S52-7.spa
dc.relation.referencesGoadsby PJ, Lipton RB, Ferrari MD. Migraine--current understanding and treatment. N Engl J Med. 2002 Jan 24;346(4):257-70.spa
dc.relation.referencesRogawski MA, Lóscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med. 2004 Jul;10(7):685-92.spa
dc.relation.referencesKelly KM. Gabapentin. Antiepileptic mechanism of action. Neuropsychobiology. 1998 Oct;38(3): 139-44.spa
dc.relation.referencesMorris GL. Gabapentin. Epilepsia. 1999;40 Suppl 5:S63- 70.spa
dc.relation.referencesGoadsby PJ. Can we develop neurally acting drugs for the treatment of migraine? Nat Rev Drug Discov. 2005 Sep;4(9):741-50.spa
dc.relation.referencesMagnus L. Nonepileptic uses of gabapentin. Epilepsia. 1999;40 Suppl 6:S66-72.spa
dc.relation.referencesGlauser TA.Topiramate.Epilepsia. 1999;40 Suppl 5:S71- 80.spa
dc.relation.referencesSilberstein SD. Practice parameter: evidence-based guidefines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Sep 26;55(6):754-62.spa
dc.relation.referencesLuo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL. Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001 Mar 15;21(6):1868-75.spa
dc.relation.referencesBayer K, Ahmadi S, Zeilhofer HU. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal hom through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology. 2004 Apr;46(5):743-9.spa
dc.relation.referencesEvans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache. 2004 Nov-Dec;44(10):1040-2.spa
dc.relation.referencesRapoport AM, Bigal ME. Migraine preventive therapy: current and emerging treatment options. Neurol Sci. 2005 May;26 Suppl 2:s111-20.spa
dc.relation.referencesChronicle E, Mulleners W.Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2004;(3):CD003226.spa
dc.relation.referencesCutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia. 1997 Apr;17(2):93-100.spa
dc.relation.referencesGraff-Radford SB. Migraine Prophylaxis. Clin Fam Pract. Sep 2005;7(3):445-62.spa
dc.relation.referencesKinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einháupl KM, Arnold G. Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache. 2001 Sep;41(8):774-8.spa
dc.relation.referencesFrediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci. 2004 Oct;25 Suppl 3:S161-6.spa
dc.relation.referencesTaylor K, Goldstein J. High-dose versus low-dose valproic acid as a prophylactic medication. Headache. 1996 Sep;36(8):514-5.spa
dc.relation.referencesMembers of the task force:, Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sándor PS. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol. 2006 Jun;13(6):560-72.spa
dc.relation.referencesJensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology. 1994 Apr;44(4): 647-51.spa
dc.relation.referencesRothrock JF, Mendizabal JE. An analysis of the "carryover effect" following successful short-term treatment of transformed migraine with divalproex sodium. Headache. 2000 Jan;40(1):17-9.spa
dc.relation.referencesSilberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002 S ep;22(7):491-512.spa
dc.relation.referencesD'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol Sci. 2007 May;28 Suppl 2:S188-97.spa
dc.relation.referencesHering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia. 1992 Apr;12(2):81-4.spa
dc.relation.referencesShaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of to- piramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache. 2006 Apr;46(4):642-8.spa
dc.relation.referencesMathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol. 1995 Mar;52(3):281-6.spa
dc.relation.referencesSilberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache. 1996 Oct;36(9):547-55.spa
dc.relation.referencesPennell PB. Pregnancy in the woman with epilepsy: maternal and fetal outcomes. Semin Neurol. 2002 Sep;22(3):299-308.spa
dc.relation.referencesStorey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache. 2001 Nov-Dec;41(10):968-75.spa
dc.relation.referencesSilberstein SD Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol Sci. 2004 Oct;25 Suppl 3:S244-5.spa
dc.relation.referencesSilberstein SD. Topiramate in migraine prevention. Headache. 2005 Apr;45 Suppl 1:S57-65.spa
dc.relation.referencesPeres MF, Mercante JP, Tanuri FC, Nunes M, Zukerman E. Chronic migraine prevention with topiramate. J Headache Pain. 2006 Sep;7(4):185-7.spa
dc.relation.referencesGupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache. 2007 Mar;47(3):402-12.spa
dc.relation.referencesRichard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influenceoftopiramate in the regulation of energy balance. Nutrition. 2000 Oct;16(10):961-6.spa
dc.relation.referencesGreenwood RS. Adverse effects of antiepileptic drugs. Epilepsia. 2000;41 Suppl 2:S42-52.spa
dc.relation.referencesCissoko H, Jonville-Béra AP, Autret-Leca E. [New antiepileptic drugs in pregnancy: outcome of 12 exponed pregnancies] Therapie. 2002 Jul-Aug;57(4):397-401.spa
dc.relation.referencesVila Cerén C, Demestre Guasch X, Raspall Torrent F, Elizari Saco MJ, Sala Castellví P, Martínez Nadal S. [Topiramate and pregnancy. Neonate with bone anomalies]An Pediatr (Barc). 2005 Oct;63(4):363-5.spa
dc.relation.referencesPetroff 0A, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gammaaminobutyric acid in patients with epilepsy.Ann Neurol. 1996 Jan;39(1):95-9.spa
dc.relation.referencesMathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001 Feb;41(2):119-28.spa
dc.relation.referencesDi Trapani G, Mei D, Marra C, Mazza S, Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ter. 2000 May-Jun;151(3):145-8.spa
dc.relation.referencesBuchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006 Apr;26(2):188-98.spa
dc.relation.referencesKrymchantowski AV, Bigal ME, Moreira PF.New and emerging prophylactic agents for migraine. CNS Drugs. 2002;16(9):611-34.spa
dc.relation.referencesSilberstein SD. Preventive treatment of migraine Trends Pharmacol Sci. 2006 Aug;27(8):410-5.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dc.identifier.eissn2462-991X
dc.identifier.urlhttps://doi.org/10.31260/RepertMedCir.v17.n3.2008.505
dc.relation.bitstreamhttps://revistas.fucsalud.edu.co/index.php/repertorio/article/download/505/548
dc.relation.citationeditionNúm. 3 , Año 2008 : Julio – Septiembrespa
dc.relation.citationendpage134
dc.relation.citationissue3spa
dc.relation.citationstartpage127
dc.relation.citationvolume17spa
dc.relation.ispartofjournalRevista Repertorio de Medicina y Cirugíaspa
dc.title.translatedAnticonvulsants: Migraine prophylaxiseng
dc.type.contentTextspa
dc.type.coarversionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.coarhttp://purl.org/coar/access_right/c_abf2spa


Files in this item

FilesSizeFormatView
Repert. Med. Cir.-505.pdf5.033Mbapplication/pdfView/Open

This item appears in the following Collection(s)

Show simple item record

Fundación Universitaria de Ciencias de la Salud FUCS - 0
Except where otherwise noted, this item's license is described as Fundación Universitaria de Ciencias de la Salud FUCS - 0